FDA's Compassion for Desperate Drug Companies
Annas, George J.
Hastings Center Report. 1990 Jan/Feb; 20(1): 35-37.
Annas is critical of recent Food and Drug Administration actions that have made experimental drugs available to critically and terminally ill patients, such as those with AIDS, outside of organized clinical trials. He chronicles shifts since 1979 in the government's position on the use of unproven drugs and devices in clinical settings. The FDA has explained its actions on the grounds of expediency and compassion for the desperately ill. Annas believes that the FDA's drive to modify or reverse its safety and efficacy standards for some drugs results from the deregulation lobbying of the pharmaceutical industry and the presence of free market advocates within the FDA. He insists that the agency is responsible for protecting the public, including the desperately ill, from harm and exploitation by upholding strict standards for drug testing. (KIE abstract)
Adults; Aids; Autonomy; Clinical Trials; Compassion; Drug Industry; Drugs; Economics; Food; Government; Government Regulation; Harm; Human Experimentation; Industry; Lobbying; Minors; Patient Care; Patients; Policy Analysis; Political Activity; Public Policy; Pharmaceutical Industry; Regulation; Research; Research Subjects; Standards; Terminally Ill; Therapeutic Research;
Showing items related by title, author, creator and subject.